Synthesis and activity of 6-substituted purine linker amino acid immunostimulants.

B Zacharie, L Gagnon, G Attardo, T P Connolly, Y St-Denis, C L Penney

Department of Medicinal Chemistry, BioChem Therapeutic Inc., Laval, Quebec.

Journal of medicinal chemistry 1997 Aug 29

filter terms:

A series of 6-substituted purinyl alkoxycarbonyl amino acids were synthesized and evaluated for their ability to stimulate cytotoxic T lymphocytes (CTLs) and the mixed lymphocyte reaction (MLR). A few of these compounds, in particular [[5-[6-(N,N-dimethylamino)purin-9-yl]pentoxy]-carbonyl]D-arginine (BCH-1393, 4a), displayed an in vitro stimulation of CTLs comparable to interleukin 2 (IL 2). BCH-1393 increased the CTL response between 10(-9) M and 10(-5) M. Further, this potent in vitro activity was reflected as a significant increase in CTL cell number in vivo. However, immunophenotyping of some of the other equipotent compounds did not reveal a parallel relative increase in CTLs in vivo. It was difficult to formulate a rigorous structure-activity relationship based on in vitro CTL activity. Nevertheless, the activity was dependent upon the nature of the 6-substituent on the purine, the type and stereochemistry of the amino acid, and the distance and spatial freedom between the purine and amino acid as defined by the length and rigidity of the linker. These compounds were generally nontoxic, as exemplified by BCH-1393. BCH-1393 is a promising immunostimulant which may be targeted for those disease states which require an increased CTL or TH1 type response.

Citation

B Zacharie, L Gagnon, G Attardo, T P Connolly, Y St-Denis, C L Penney. Synthesis and activity of 6-substituted purine linker amino acid immunostimulants. Journal of medicinal chemistry. 1997 Aug 29;40(18):2883-94